{"id":"W4400143109","doi":"10.1016/j.annonc.2024.05.185","title":"176P Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Servier; National Natural Science Foundation of China; Sierra Oncology; Incyte; Ipsen; BeiGene; Eisai; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Astellas Pharma; Novocure; Boston Scientific Corporation; Yuhan; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Lenvatinib; Medicine; Hepatocellular carcinoma; Pharmacodynamics; Open label; Oncology; Pharmacology; Internal medicine; Sorafenib; Pharmacokinetics; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006778929,0.000955735,0.001625684,0.0003678772,0.0003134936,0.001040911,0.0003894971,0.0008144691,0.003886287],"category_scores_gemma":[0.0005701896,0.0004923128,0.001342193,0.0003278924,0.0006331073,0.0008063156,0.0001936662,0.002619492,0.0008772371],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001079501,"about_ca_system_score_gemma":0.0009312166,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001271118,"about_ca_topic_score_gemma":0.003176155,"domain_scores_codex":[0.9997353,0.0001160119,0.00001171003,0.0000419415,0.000024603,0.00007046086],"domain_scores_gemma":[0.9997496,0.00004327365,0.00004760837,0.0000234127,0.00001608611,0.0001200874],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.772397,0.03394859,0.005885774,0.0006719765,0.002099255,0.0004320668,0.00019871,0.003759246,0.06651741,0.000406672,0.004235285,0.1094481],"study_design_scores_gemma":[0.3709966,0.587752,0.02145641,0.00005829066,0.001162473,0.0005040311,0.0001020731,0.002835793,0.009615332,0.0002578548,0.005172116,0.00008696737],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951689,0.001418035,0.000240929,0.0002915244,0.00009765524,0.0004067283,0.0006681036,0.00005998039,0.001648191],"genre_scores_gemma":[0.9943445,0.0009407634,0.0004747048,0.0003992643,0.00009649967,0.0003909389,0.001135133,0.00002484152,0.002193383],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003886287,"threshold_uncertainty_score":0.01300091,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2338540012610092,"score_gpt":0.4176022382086809,"score_spread":0.1837482369476717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}